Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;303(3):673-674.
doi: 10.1148/radiol.213015. Epub 2022 Mar 1.

Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma

Mizuki Nishino  1
Affiliations
Editorial

Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma

Mizuki Nishino. Radiology. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures of Conflicts of Interest: institutional research grants from AstraZeneca, Daiichi Sankyo, and Canon Medical Systems; consulting fee from AstraZeneca and Daiichi Sankyo; Diagnosis Please editor for the Radiology editorial board.

Figures

Mizuki Nishino, MD, MPH, is a professor of radiology at Harvard Medical School and a thoracic radiologist at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Her research focuses on imaging of lung cancer for precision oncology. She is a member of the Fleischner Society, serves as a Diagnosis Please editor for the Radiology editorial board, and is a member for the NIH Emerging Imaging Technologies and Applications study section.
Mizuki Nishino, MD, MPH, is a professor of radiology at Harvard Medical School and a thoracic radiologist at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Her research focuses on imaging of lung cancer for precision oncology. She is a member of the Fleischner Society, serves as a Diagnosis Please editor for the Radiology editorial board, and is a member for the NIH Emerging Imaging Technologies and Applications study section.
See this image and copyright information in PMC

Comment on

References

    1. Nishino M , Hatabu H , Johnson BE , McLoud TC . State of the art: Response assessment in lung cancer in the era of genomic medicine . Radiology 2014. ; 271 ( 1 ): 6 – 27 . - PMC - PubMed
    1. Park H , Sholl LM , Hatabu H , Awad MM , Nishino M . Imaging of Precision Therapy for Lung Cancer: Current State of the Art . Radiology 2019. ; 293 ( 1 ): 15 – 29 . - PMC - PubMed
    1. Wu YL , Tsuboi M , He J , et al . Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer . N Engl J Med 2020. ; 383 ( 18 ): 1711 – 1723 . - PubMed
    1. Felip E , Altorki N , Zhou C , et al . Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial . Lancet 2021. ; 398 ( 10308 ): 1344 – 1357 . - PubMed
    1. Perez-Johnston R , Araujo-Filho JA , Connolly JG , et al . CT-based radiogenomic analysis of clinical stage I lung adenocarcinoma with histopathologic features and oncologic outcomes . Radiology 2022. ; 303 ( 3 ): 664 – 672 . - PMC - PubMed